Microbot Medical gains first North Carolina customer for robotic system
Get Alerts MBOT Hot Sheet
Join SI Premium – FREE
Microbot Medical Inc. (NASDAQ: MBOT) announced it secured its first customer in North Carolina for its LIBERTY Endovascular Robotic System, according to a company press release. The healthcare system operates a multi-hospital network across the state and represents the company's expansion into the Southeast and Mid-Atlantic regions.
The Massachusetts-based medical device company described the customer as a leading academic center, marking what it called the first adoption in the Southeast and Mid-Atlantic region. The announcement follows the full market release of the LIBERTY system, which the company describes as a single-use, remotely operated robotic solution for endovascular procedures.
"It's exciting to see the pace of increase in new accounts following the full market release of the LIBERTY system, including our newest territories in the Northeast and South-Atlantic, as some of the nation's leading health systems are adopting LIBERTY system," said Harel Gadot, CEO, President and Chairman of Microbot Medical.
The company stated it expects to penetrate other major metropolitan markets and academic institutions. Microbot Medical develops and distributes robotic technology for endovascular procedures and holds intellectual property related to its robotic systems.
The LIBERTY system received regulatory approval for commercial use, though the press release did not specify when the North Carolina healthcare system will begin using the technology or provide financial terms of the agreement.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
- NVE Corp CEO to retire, successor named for August transition
- Guardian Pharmacy names new COO and CFO, effective July 2026
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share